• 1
    Guerrini R, Parmeggiani L. Topiramate and its clinical applications in epilepsy. Expert Opin Pharmacother 2006; 7: 81123.
  • 2
    Ramadan NM, Buchanan TM. New and future migraine therapy. Pharmacol Ther 2006; 112: 199212.
  • 3
    Vasudev K, Macritchie K, Geddes J, Watson S, Young A. Topiramate for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev 2006; 1: CD003384.
  • 4
    Berlin HA. Antiepileptic drugs for the treatment of post-traumatic stress disorder. Curr Psychiatry Rep 2007; 9: 291300.
  • 5
    Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2008; 13: 38392.
  • 6
    Baltieri DA, Daro FR, Ribeiro PL, De Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008; 103: 203544.
  • 7
    McElroy SL, Guerdjikova AI, Martens B, Keck PE, Pope HG, Hudson JI. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs 2009; 23: 13956.
  • 8
    Hollander E, Dell'Osso B. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol 2006; 21: 18991.
  • 9
    Celebisoy N, Gokcay F, Sirin H, Akyurekli O. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 2007; 116: 3227.
  • 10
    Bendaly EA, Jordan CA, Staehler SS, Rushing DA. Topiramate in the treatment of neuropathic pain in patients with cancer. Support Cancer Ther 2007; 4: 2416.
  • 11
    Zou LP, Lin Q, Qin J, Cai FC, Liu ZS, Mix E. Evaluation of open-label topiramate as primary or adjunctive therapy in infantile spasms. Clin Neuropharmacol 2008; 31: 8692.
  • 12
    Campayo JG, Sobradiel N, Alda M, Mas A, Andres E, Magallon R, Crucelaegui A, Sanz B. Effectiveness of topiramate for tobacco dependence in patients with depression; a randomised, controlled trial. BMC Fam Pract 2008; 9: 28.
  • 13
    Burmeister JE, Pereira RR, Hartke EM, Kreuz M. Topiramate and severe metabolic acidosis: case report. Arq Neuropsiquiatr 2005; 63: 5324.
  • 14
    Ozer Y, Altunkaya H. Topiramate induced metabolic acidosis. Anaesthesia 2004; 59: 830.
  • 15
    Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 2002; 43: 7447.
  • 16
    Garris SS, Oles KS. Impact of topiramate on serum bicarbonate concentrations in adults. Ann Pharmacother 2005; 39: 4246.
  • 17
    Welch BJ, Graybeal D, Moe OW, Maalouf NM, Sakhaee K. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis 2006; 48: 55563.
  • 18
    Laing CM, Unwin RJ. Renal tubular acidosis. J Nephrol 2006; 19 (Suppl. 9): S4652.
  • 19
    Izzedine H, Launay-Vacher V, Deray G. Topiramate-induced renal tubular acidosis. Am J Med 2004; 116: 2812.
  • 20
    Sacre A, Jouret F, Manicourt D, Devuyst O. Topiramate induces type 3 renal tubular acidosis by inhibiting renal carbonic anhydrase. Nephrol Dial Transplant 2006; 21: 29956.
  • 21
    Stowe CD, Bollinger T, James LP, Haley TM, Griebel ML, Farrar HC 3rd. Acute mental status changes and hyperchloremic metabolic acidosis with long-term topiramate therapy. Pharmacotherapy 2000; 20: 1059.
  • 22
    Warner BW, LaGrange CA, Tucker T, Bensalem-Owen M, Pais VM Jr. Induction of progressive profound hypocitraturia with increasing doses of topiramate. Urology 2008; 72: 2932; discussion 32–3.
  • 23
    Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA. The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol 2006; 26: 35260.
  • 24
    Weber S, Soergel M, Jeck N, Konrad M. Atypical distal renal tubular acidosis confirmed by mutation analysis. Pediatr Nephrol 2000; 15: 2014.
  • 25
    Bregman H, Brown J, Rogers A, Bourke E. Osteopetrosis with combined proximal and distal renal tubular acidosis. Am J Kidney Dis 1982; 2: 35762.
  • 26
    Ohlsson A, Cumming WA, Paul A, Sly WS. Carbonic anhydrase II deficiency syndrome: recessive osteopetrosis with renal tubular acidosis and cerebral calcification. Pediatrics 1986; 77: 37181.
  • 27
    Vainsel M, Fondu P, Cadranel S, Rocmans C, Gepts W. Osteopetrosis associated with proximal and distal tubular acidosis. Acta Paediatr Scand 1972; 61: 42934.
  • 28
    Nagai R, Kooh SW, Balfe JW, Fenton T, Halperin ML. Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency: pathogenesis of impaired acidification. Pediatr Nephrol 1997; 11: 6336.
  • 29
    Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci USA 1983; 80: 27526.
  • 30
    McMahon C, Will A, Hu P, Shah GN, Sly WS, Smith OP. Bone marrow transplantation corrects osteopetrosis in the carbonic anhydrase II deficiency syndrome. Blood 2001; 97: 194750.
  • 31
    Purkerson JM, Schwartz GJ. The role of carbonic anhydrases in renal physiology. Kidney Int 2007; 71: 10315.
  • 32
    Winum JY, Poulsen SA, Supuran CT. Therapeutic applications of glycosidic carbonic anhydrase inhibitors. Med Res Rev 2009; 29: 41935.
  • 33
    Maryanoff BE, McComsey DF, Costanzo MJ, Hochman C, Smith-Swintosky V, Shank RP. Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J Med Chem 2005; 48: 19417.
  • 34
    Innocenti A, Hilvo M, Scozzafava A, Lindfors M, Nordlund HR, Kulomaa MS, Parkkila S, Supuran CT. Carbonic anhydrase inhibitors: the very weak inhibitors dithiothreitol, beta-mercaptoethanol, tris(carboxyethyl)phosphine and threitol interfere with the binding of sulfonamides to isozymes II and IX. Bioorg Med Chem Lett 2008; 18: 1898903.
  • 35
    Recacha R, Costanzo MJ, Maryanoff BE, Chattopadhyay D. Crystal structure of human carbonic anhydrase II complexed with an anti-convulsant sugar sulphamate. Biochem J 2002; 361: 43741.
  • 36
    Tartara A, Sartori I, Manni R, Galimberti CA, Di Fazio M, Perucca E. Efficacy and safety of topiramate in refractory epilepsy: a long-term prospective trial. Ital J Neurol Sci 1996; 17: 42932.
  • 37
    Lotti T. Introduction. Urol Int 2007; 79 (Suppl. 1): 37.
  • 38
    Wasserstein AG, Rak I, Reife RA. Nephrolithiasis during treatment with topiramate. Epilepsia 1995; 36: S153S53.
  • 39
    Lamb EJ, Stevens PE, Nashef L. Topiramate increases biochemical risk of nephrolithiasis. Ann Clin Biochem 2004; 41: 1669.
  • 40
    Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure 2008; 17: 1816.
  • 41
    Ensrud KE, Walczak TS, Blackwell TL, Ensrud ER, Barrett-Connor E, Orwoll ES. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 2008; 71: 72330.
  • 42
    Lyngstad-Brechan MA, Tauboll E, Nakken KO, Gjerstad L, Godang K, Jemtland R, Bollerslev J. Reduced bone mass and increased bone turnover in postmenopausal women with epilepsy using antiepileptic drug monotherapy. Scand J Clin Lab Invest 2008; 68: 75966.
  • 43
    Pirmohamed M, Ferner RE. Monitoring drug treatment. BMJ 2003; 327: 117981.
  • 44
    McSherry E. Renal tubular acidosis in childhood. Kidney Int 1981; 20: 799809.
  • 45
    Brenner RJ, Spring DB, Sebastian A, McSherry EM, Genant HK, Palubinskas AJ, Morris RCJr . Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis. N Engl J Med 1982; 307: 21721.
  • 46
    Wiśniewski M, Łukasik-Głebocka M, Anand JS. Acute topiramate overdose – clinical manifestations. Clin Toxicol (Phil) 2009; 47: 31720.
  • 47
    Klinger AL, McComsey DF, Smith-Swintosky V, Shank RP, Maryanoff BE. Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem 2006; 49: 3496500.